PDCD1 and neoplasm: However, under the same conditions, rhIL-7-hyFc treatment alone demonstrated moderate antitumor efficacy, and the combination of rhIL-7-hyFc and anti-PD-1 dramatically inhibited tumor growth, nearly achieving complete regression.